Alaa Hamed Salama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alaa Hamed Salama has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Adel Ahmed Ali
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt
3 shared publications - Azza Ahmed Mahmoud
Pharmaceutics and Pharmaceutical Technology Department, Faculty of Pharmacy, Future University in Egypt, New Cairo, Egypt
3 shared publications - Hussein Osman Ammar
Department of Pharmaceutical Technology, National Research Center, Dokki, Cairo, Egypt
3 shared publications - Rabab Kamel
Pharmaceutical Technology Department, National Research Centre, Cairo, Egypt
3 shared publications Abeer A.A. Salama
Pharmacology Department, Medical Research Division, National Research Centre, Dokki, Cairo, 12622 Egypt
2 shared publicationsGhada Abdelsabour Moubarak
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Ahram Canadian University, 6th of October city, Giza, Egypt
2 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 37
Development of Novel Olmesartan Medoxomil Loaded Leciplex for Enhanced Oral Bioavailability: Formulation, Histopathological Analysis, and In Vivo Pharmacokinetic Studies
Olmesartan medoxomil (OLM), a widely prescribed antihypertensive agent, suffers from poor solubility and first pass metabolism, which lowers its bioavailability. This work aimed to develop novel cationic nanocarriers (LeciPlex) for OLM to enhance its dissolution and oral bioavailability. A central composite design (CCD) was employed to optimize OLM-loaded LeciPlex (OLM-LPX) formulations. The independent variables included lecithin amount, surfactant amount, and surfactant type. The influence of these factors on particle size (PS), entrapment efficiency (EE), surface charge (ZP), and cumulative in vitro drug release (CR) was thoroughly evaluated and examined. The optimized formulation underwent additional evaluation for ex vivo permeation, morphology, stability, in vivo histopathology, and pharmacokinetic studies. The optimized OLM-LPX exhibited desirable PS (149.23 ± 2.02 nm), ZP (+ 62.03 ± 2.45 mV), EE (82.25 ± 4.63%), and CR (88.87 ± 1.97% after 8 h), aligning well with the predicted CCD values. Ex vivo permeation of optimized OLM-LPX across rabbit intestine showed a cumulative OLM transport of 1973.1 ± 207.9 µg versus 909.9 ± 217.8 µg for OLM suspension, with a permeability coefficient 3.4-fold higher and a 2.17-fold increase in intestinal permeability. Transmission electron microscope images showed spherical-shaped and smooth particles. It also exhibited accepted stability over the predetermined storage period (90 days), showing neither sedimentation nor particle coalescence. The orally administered optimized OLM-LPX showed no evidence for inflammatory signs or mucosal damage within intestinal gut segments under histopathological examination. Pharmacokinetic evaluation in rats demonstrated that OLM-LPX achieved a C max of 3.48 ± 0.25 µg/mL versus 1.32 ± 0.21 µg/mL for suspension, extended t max (2 h vs. 1 h), and a markedly enhanced AUC ₀–∞ of 41.17 ± 3.41 µg·mL⁻¹·h compared to 11.48 ± 1.69 µg·mL⁻¹·h, corresponding to a relative bioavailability of 358.62%. Collectively, LPX may serve as an effective nanocarrier for effective oral administration of poorly soluble OLM, contributing to its enhanced bioavailability. Graphical Abstract
- 25 November 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 37
Open AccessDevelopment of Novel Olmesartan Medoxomil Loaded Leciplex for Enhanced Oral Bioavailability: Formulation, Histopathological Analysis, and In Vivo Pharmacokinetic Studies
Olmesartan medoxomil (OLM), a widely prescribed antihypertensive agent, suffers from poor solubility and first pass metabolism, which lowers its bioavailability. This work aimed to develop novel cationic nanocarriers (LeciPlex) for OLM to enhance its dissolution and oral bioavailability. A central composite design (CCD) was employed to optimize OLM-loaded LeciPlex (OLM-LPX) formulations. The independent variables included lecithin amount, surfactant amount, and surfactant type. The influence of these factors on particle size (PS), entrapment efficiency (EE), surface charge (ZP), and cumulative in vitro drug release (CR) was thoroughly evaluated and examined. The optimized formulation underwent additional evaluation for ex vivo permeation, morphology, stability, in vivo histopathology, and pharmacokinetic studies. The optimized OLM-LPX exhibited desirable PS (149.23 ± 2.02 nm), ZP (+ 62.03 ± 2.45 mV), EE (82.25 ± 4.63%), and CR (88.87 ± 1.97% after 8 h), aligning well with the predicted CCD values. Ex vivo permeation of optimized OLM-LPX across rabbit intestine showed a cumulative OLM transport of 1973.1 ± 207.9 µg versus 909.9 ± 217.8 µg for OLM suspension, with a permeability coefficient 3.4-fold higher and a 2.17-fold increase in intestinal permeability. Transmission electron microscope images showed spherical-shaped and smooth particles. It also exhibited accepted stability over the predetermined storage period (90 days), showing neither sedimentation nor particle coalescence. The orally administered optimized OLM-LPX showed no evidence for inflammatory signs or mucosal damage within intestinal gut segments under histopathological examination. Pharmacokinetic evaluation in rats demonstrated that OLM-LPX achieved a C max of 3.48 ± 0.25 µg/mL versus 1.32 ± 0.21 µg/mL for suspension, extended t max (2 h vs. 1 h), and a markedly enhanced AUC ₀–∞ of 41.17 ± 3.41 µg·mL⁻¹·h compared to 11.48 ± 1.69 µg·mL⁻¹·h, corresponding to a relative bioavailability of 358.62%. Collectively, LPX may serve as an effective nanocarrier for effective oral administration of poorly soluble OLM, contributing to its enhanced bioavailability. Graphical Abstract
- Open Access
- 13 August 2025
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 11 (1) , 1-23
Recent advances in 3D and 4D printing in pharmaceutical technology: applications, challenges, and future perspectives
Background: The conventional drug delivery devices always present a “one-size-fits-all” approach which limits their application in pharmaceutical industry, because of their inability to adapt to individual pharmacokinetic features. Three-dimensional (3D) printing is the most economical substitutes for transferring from the “one-size-fits-all” approach (i.e., mass production) to fabricate small individualized batches. Main text: 3D printing, advanced by the additive manufacturing technology, has gained growing demanding and popularity to develop pharmaceutical dosage forms and medical devices; and offered much more preferences over the traditional fabrication technologies. This advanced technology presents the ability of fabricating customizable design, 3D structures with sophisticated architecture, intended for personalized treatment. As a further advancement, the emergence of four-dimensional (4D) printing extensively contributed to the advancement of personalized medication by combining the benefits of smart multiple functional materials with the 3D printing technology. In spite of all of the offered notable progresses in both techniques, some regulatory issues, scalability, and production cost present key obstruction. Conclusions: In the present article, an overview on the latest research articles demonstrating some step forward accomplishments for exploiting 3D and 4D printing technologies in developing advanced pharmaceutical dosage forms, medical devices, and tissue engineering as well as presenting the foremost challenges and future perspectives. Graphical
- 13 August 2025
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 11 (1) , 1-23
Open AccessRecent advances in 3D and 4D printing in pharmaceutical technology: applications, challenges, and future perspectives
Background: The conventional drug delivery devices always present a “one-size-fits-all” approach which limits their application in pharmaceutical industry, because of their inability to adapt to individual pharmacokinetic features. Three-dimensional (3D) printing is the most economical substitutes for transferring from the “one-size-fits-all” approach (i.e., mass production) to fabricate small individualized batches. Main text: 3D printing, advanced by the additive manufacturing technology, has gained growing demanding and popularity to develop pharmaceutical dosage forms and medical devices; and offered much more preferences over the traditional fabrication technologies. This advanced technology presents the ability of fabricating customizable design, 3D structures with sophisticated architecture, intended for personalized treatment. As a further advancement, the emergence of four-dimensional (4D) printing extensively contributed to the advancement of personalized medication by combining the benefits of smart multiple functional materials with the 3D printing technology. In spite of all of the offered notable progresses in both techniques, some regulatory issues, scalability, and production cost present key obstruction. Conclusions: In the present article, an overview on the latest research articles demonstrating some step forward accomplishments for exploiting 3D and 4D printing technologies in developing advanced pharmaceutical dosage forms, medical devices, and tissue engineering as well as presenting the foremost challenges and future perspectives. Graphical
- 10 October 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 112 (3) , 760-770
Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats
- 10 October 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 112 (3) , 760-770
Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats
- Open Access
- 20 December 2021
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 45 (1) , 1-7
Effect of experimental moringa and propolis toothpastes on surface microhardness of simulated hypersensitive dentin
Objective: Objective was to investigate the effect of NovaMin toothpaste and two experimental toothpastes on surface microhardness of hypersensitive dentin. Methods: Eighty specimens were prepared and divided randomly into eight groups (n = 10/group) according to the tested toothpastes (NovaMin, moringa and propolis toothpastes) and the acidic challenge (with or without 6% citric acid challenge). Enamel surfaces were removed, and the dentin surfaces were exposed on which the three tested toothpastes were brushed twice a day for 1 week using an electric toothbrush, then a 4-d citric acid cycling model with pH 5 was performed. The prepared specimens were stored in artificial saliva until the microhardness test was performed. Statistical analysis was done using One-way ANOVA followed by Tukey post hoc test. Results: NovaMin-containing toothpaste showed an increased dentin surface microhardness following a week of twice daily brushing compared to other groups. However, NovaMin-containing toothpaste showed the highest microhardness values following pH cycling with citric acid of pH 5 compared to other tested groups. Conclusions: NovaMin-containing toothpaste showed a partial recovery of dentin microhardness at pH 5 during the acidic challenge. Moreover, propolis- and moringa-containing toothpastes had an insignificant effect on dentin surface microhardness with and without citric acid challenge.
- 20 December 2021
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 45 (1) , 1-7
Open AccessEffect of experimental moringa and propolis toothpastes on surface microhardness of simulated hypersensitive dentin
Objective: Objective was to investigate the effect of NovaMin toothpaste and two experimental toothpastes on surface microhardness of hypersensitive dentin. Methods: Eighty specimens were prepared and divided randomly into eight groups (n = 10/group) according to the tested toothpastes (NovaMin, moringa and propolis toothpastes) and the acidic challenge (with or without 6% citric acid challenge). Enamel surfaces were removed, and the dentin surfaces were exposed on which the three tested toothpastes were brushed twice a day for 1 week using an electric toothbrush, then a 4-d citric acid cycling model with pH 5 was performed. The prepared specimens were stored in artificial saliva until the microhardness test was performed. Statistical analysis was done using One-way ANOVA followed by Tukey post hoc test. Results: NovaMin-containing toothpaste showed an increased dentin surface microhardness following a week of twice daily brushing compared to other groups. However, NovaMin-containing toothpaste showed the highest microhardness values following pH cycling with citric acid of pH 5 compared to other tested groups. Conclusions: NovaMin-containing toothpaste showed a partial recovery of dentin microhardness at pH 5 during the acidic challenge. Moreover, propolis- and moringa-containing toothpastes had an insignificant effect on dentin surface microhardness with and without citric acid challenge.
- 13 October 2020
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 21 (7) , 283
Formulation and Evaluation of Novel Hybridized Nanovesicles for Enhancing Buccal Delivery of Ciclopirox Olamine
Ciclopirox olamine (CPO) is a topical wide-spectrum antimycotic agent that possesses antifungal, antibacterial and anti-inflammatory activities. Loading CPO into a hybridized vesicular system is expected to enhance its buccal permeation and hence, therapeutic activity, whereas the frequent administration and side effects are reduced. Vesicular systems with high penetration ability were prepared based on cholesterol, Lipoid S45 or Phospholipon 90H, with span 60 while incorporating a penetration enhancer (Labrafac or labrasol) followed by full assessment of their size, entrapment efficiency, and drug release profiles. The optimum formulation, composed of Lipoid S45 and Labrafac, possessed the smallest vesicle size (346.1 nm), highest entrapment efficiency (94.4%), and sustained CPO release pattern, and was characterized for its morphology and thermal properties. This powerful mixture of the penetration enhancers (Lipoid S45 and Labrafac) in the designed hybridized vesicles was thoroughly investigated for their characteristics after being incorporated in bioadhesive gel. Moreover, enhanced antifungal activity was demonstrated either upon testing the designed formulation on agar plates or in vivo upon treating infected rabbits with the proposed formulation. Results suggest that the presented bioadhesive gel incorporating the CPO-loaded vesicles can be a promising delivery system that can offer a prolonged localized antifungal treatment with enhanced therapeutic effect.
- 13 October 2020
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 21 (7) , 283
Formulation and Evaluation of Novel Hybridized Nanovesicles for Enhancing Buccal Delivery of Ciclopirox Olamine
Ciclopirox olamine (CPO) is a topical wide-spectrum antimycotic agent that possesses antifungal, antibacterial and anti-inflammatory activities. Loading CPO into a hybridized vesicular system is expected to enhance its buccal permeation and hence, therapeutic activity, whereas the frequent administration and side effects are reduced. Vesicular systems with high penetration ability were prepared based on cholesterol, Lipoid S45 or Phospholipon 90H, with span 60 while incorporating a penetration enhancer (Labrafac or labrasol) followed by full assessment of their size, entrapment efficiency, and drug release profiles. The optimum formulation, composed of Lipoid S45 and Labrafac, possessed the smallest vesicle size (346.1 nm), highest entrapment efficiency (94.4%), and sustained CPO release pattern, and was characterized for its morphology and thermal properties. This powerful mixture of the penetration enhancers (Lipoid S45 and Labrafac) in the designed hybridized vesicles was thoroughly investigated for their characteristics after being incorporated in bioadhesive gel. Moreover, enhanced antifungal activity was demonstrated either upon testing the designed formulation on agar plates or in vivo upon treating infected rabbits with the proposed formulation. Results suggest that the presented bioadhesive gel incorporating the CPO-loaded vesicles can be a promising delivery system that can offer a prolonged localized antifungal treatment with enhanced therapeutic effect.